The vision of NETRIS Pharma is to make a significant contribution to the development of innovative therapeutic molecules for treating cancer by targeting Dependence Receptors.

NETRIS PHARMA IS RECOGNIZED FOR ITS ABILITY TO TRANSLATE OUTSTANDING RESEARCH INTO INNOVATIVE AND BENEFICIAL TREATMENTS FOR CANCER

NETRIS Pharma identifies and develops therapeutic molecules and more specifically monoclonal antibodies (mAbs) that, tomorrow, will become new tools for the targeted treatment of cancer.

NETRIS Pharma is investigating the recently identified Dependence Receptor transducing pathways. NETRIS Pharma is a pioneer in this field of research and is establishing itself as an international leader.

The company has received numerous awards and distinctions from public and private institutions and has been accorded several national and european grants

  • fundings from Agence Nationale de la Recherche (TROY program with NETRIS as industrial partner) in 2016
  • fundings from Europe (European FP7-Health Innovation program) in 2013
  • fundings from Agence Nationale de la Recherche (BiotecS and RPIB programs) in 2008 and 2013
  • the « Tremplin Entreprise Senat » award, a selection of the 30 most promising French ventures in 2008
  • the competitive cluster Lyonbiopole label
  • the « Novacité » endorsement from the Lyon Chamber of Commerce (CCI) in 2008
  • laureates and related subsidies of the Innovation Award from Ministry of Research (Oseo « Emergence » 2006, Oseo « Creation, Development » 2008)

Localisation

The company is located in Lyon (France) within the Léon Bérard comprehensive cancer center.

Through its translational research activity, NETRIS Pharma represents an essential link between both the basic and the clinical research performed by the Léon Bérard Center. The company hastens the application of the most recent research on the role of Dependence Receptors in cancer, for the benefit of the patient.

NETRIS Pharma is also a partner in several plan d’investissement d’avenir programs such as the laboratoire d’excellence devwecan and the equipement d’excellence phenocan